Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Low-dose finasteride may cause muscle weakness and eye issues, but stopping the drug can lead to recovery.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.

In this study, low-dose finasteride (2.5 mg/day) significantly reduced hirsutism scores in women over 12 months without significant hormonal changes or serious side effects.

This study observed that low-dose intrauterine exposure to finasteride alters postnatal prostate development in male and female Mongolian gerbils, showing sex-specific differences in receptor expression and tissue changes.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

Both treatment combinations improved hair growth similarly and were safe.

This study found that an intermittent low-dose regimen of finasteride (2.5 mg every 3 days) effectively reduced hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome, with fewer side effects than continuous daily administration.

This study found that a low-dose intermittent finasteride regimen significantly reduced hirsutism scores in adolescent girls with PCOS or idiopathic hirsutism, with similar efficacy but potentially safer and less expensive than continuous administration.

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.

This study found that a low dose of finasteride over 12 weeks did not alter the lipid profile or adiposity index in atheroprone Ldlr−/− mice.

In this study, a daily low-dose regimen of oral minoxidil and finasteride over 12 months led to significant hair density improvements in over 92% of adult men with androgenetic alopecia, including those with advanced stages, though inter-rater reliability in photo assessments was modest.

This study found that adding low-dose dutasteride to ongoing finasteride treatment significantly improved hair density in a patient with androgenetic alopecia.

This study found that both high-dose and low-dose finasteride significantly reduced hirsutism scores in women after 12 months, with the lower dose being safe and cost-effective.

This case report describes a 40-year-old man whose secondary infertility, observed after prolonged finasteride use for hair loss, resolved following discontinuation of the drug, resulting in a live birth.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

This case report highlights a persistent gynecomastia in a young man following low-dose finasteride, suggesting that the incidence may be underreported and calls for patient counseling and early intervention.

This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

This case report describes a 23-year-old man experiencing painful gynecomastia aggravated by low dose finasteride for androgenetic alopecia, which reversed after stopping the medication.

In this large retrospective study, low-dose finasteride for androgenetic alopecia was associated with an increased risk of erectile dysfunction at one and three years among men aged 18-45.

This study aimed to assess whether using minoxidil alongside nutritional cyclical supplements could boost hair regrowth without antiandrogens or enzyme blockers, focusing on hair root strengthening. Results are not reported.

In this study, long-term low-dose finasteride use in men with alopecia was associated with a significant reduction in the diagnosis of benign prostatic hyperplasia and prostate cancer, although further research is needed to understand the mechanisms and long-term effects.

This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

In this correspondence, researchers reported that very-low-dose oral minoxidil (0.25 mg/d) showed some effectiveness in stabilizing trichoscopic parameters in male androgenetic alopecia. However, their analysis suggests that higher doses (2.5–5 mg/d) may lead to better clinical responses with similar rates of adverse events.